ADAM17 and Miyoshi myopathy: Consistently, our results demonstrated that downregulation of SPAG5 decreased the expression of FOXM1, ADAM17 and NOTCH1, which was counteracted by overexpression of FOXM1, suggesting that silencing of SPAG5 inhibited ADAM17/NOTCH1 signaling through downregulating of FOXM1 expression in MM cells.